Drug intelligence / Profile preview

P7435

Development stage: Discontinued
Lead developer: Piramal Enterprises
Modality: Small Molecules
Administration: Oral

Overview

P7435 is a small molecule drug developed by Piramal Phytocare Ltd. It acts as a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor. DGAT1 is involved in lipid metabolism, and inhibiting it can reduce triglyceride levels, glucose, and insulin levels, which are associated with metabolic disorders like diabetes and dyslipidemias. P7435 was initially developed for managing metabolic disorders but its R&D status is currently discontinued.

Targets

DGAT1 (Diacylglycerol O-acyltransferase 1)

Beyond the preview

Go deeper on P7435.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P7435.

Explore the full profile